Patronus AI unveiled “Generative Simulators,” adaptive “practice worlds” that replace static benchmarks with dynamic ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

C compiler, LustreC, into a generator of both executable code and associated specification. Model-based design tools are ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

Every year, Guruvayur Ekadashi — also observed as Gita Jayanti — reminds us of the power of reflection and conversation.

It’s not the rogue AI from science fiction that should be keeping industry leaders up at night. It’s the sneakily rapid pace of autonomy that’s happening in their own laboratories. Jared Kaplan, of ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...